Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Generative Artificial Intelligence (AI) In Drug Discovery Market Poised To Hit $0.86 Billion By 2030 With A 27% CAGR
The generative artificial intelligence (AI) in drug discovery market size has experienced substantial expansion in recent years. Its value is anticipated to rise from $0.25 billion in 2025 to $0.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 30.6%. This historical growth can be linked to elevated drug development costs, the evolution of computational chemistry, the increasing availability of biological datasets, the integration of machine learning tools, and considerable pharmaceutical R&D investment.
The market for generative artificial intelligence (AI) in drug discovery is projected to experience substantial expansion over the coming years. This market is forecast to reach $0.86 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 27.0%. Key factors driving this growth during the forecast period include the integration of generative models into discovery pipelines, a heightened demand for more rapid drug discovery, the broadening scope of biologics optimization, increased collaboration between AI companies and pharmaceutical firms, and a decrease in time-to-market. Noteworthy trends anticipated in the same period involve the increasing adoption of AI-driven molecule generation, a surge in the application of deep learning for drug design, the broadening of small molecule discovery applications, enhanced integration of AI in lead optimization, and the acceleration of early-stage drug development processes.
Get A Free Sample Report With In-Depth Market Insights:
Generative Artificial Intelligence (AI) In Drug Discovery Market Growth Momentum: What Factors Are Shaping Demand?
The expanding volume of clinical trials is anticipated to boost the advancement of generative AI in the drug discovery market. These trials, involving human participants, evaluate the safety and effectiveness of new medical treatments or procedures, aiming to gather scientific evidence for their human application. This increase in trials is primarily attributed to progress in medical research, a greater burden of disease, evolving regulatory frameworks, globalized clinical research efforts, patient advocacy and awareness, market competition, technological breakthroughs, and increased funding opportunities. Data from clinical trials powers generative AI models, accelerating drug discovery by forecasting interactions and designing compounds. This collaboration fosters personalized medicine, enhances treatment effectiveness, improves patient results, and transforms the pharmaceutical sector. For example, according to Pharmaceutical Technology, a UK-based business news and media company, in January 2025, 3,213 trials are scheduled to commence this year, including 823 in Phase I and 1,102 in Phase II. Consistent with 2024, oncology is projected to be the leading therapeutic area, accounting for 946 trials, followed by the central nervous system with 686 trials, and then cardiovascular considerably behind with 258 trials. Consequently, the increasing number of clinical trials is propelling the expansion of generative AI in the drug discovery market.
Generative Artificial Intelligence (AI) In Drug Discovery Market Segmentation And Category Overview
The generative artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Machine Learning, Reinforcement Learning, Molecular Docking, Quantum Computing
3) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutions, Contract Research Organizations (CROs), Other End-Users
Subsegments:
1) By Small Molecule: Drug Design And Optimization, Lead Discovery And Identification, Toxicology Prediction, Molecular Property Prediction, ADMET (Absorption, Distribution, Metabolism, Excretion, And Toxicity) Prediction
2) By Large Molecule: Protein Structure Prediction, Antibody Design, Biologics Optimization, Peptide Design, Biopharmaceutical Discovery And Optimization
Generative Artificial Intelligence (AI) In Drug Discovery Market Trends: What’s Defining The Industry’s Next Phase?
Key companies active in the generative AI in the drug discovery market are crafting advanced AI-driven instruments to speed up drug discovery processes. These AI-powered tools hasten drug development by streamlining drug discovery, design, and clinical trials through predictive analytics and machine learning. They improve efficiency in areas such as target identification and compound screening, including virtual screening using AI, preclinical development, regulatory compliance, and manufacturing processes. For instance, in May 2023, Google Cloud, a US-based cloud computing service provided by Google, launched two cutting-edge AI-powered solutions. These solutions, named the Target and Lead Identification Suite and the Multiomics Suite, aim to enhance drug discovery and precision medicine across biotech, pharmaceutical, and public sector organizations. The Target and Lead Identification Suite assists researchers in understanding amino acid functions and predicting protein structures, while the Multiomics Suite expedites the analysis and comprehension of genomic data, making the development of personalized treatments simpler.
Generative Artificial Intelligence (AI) In Drug Discovery Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrödinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc., DeepMatter Group Limited, Variational AI Inc
View The Full Generative Artificial Intelligence (AI) In Drug Discovery Market Report:
Generative Artificial Intelligence (AI) In Drug Discovery Market Top Region By Revenue And Market Share
North America was the largest region in the generative AI in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









